PLB1004 trials for Lung cancer

All PLB1004 trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying PLB1004 for Lung cancer

• A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
  NCT06046495 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
  NCT07336732 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
  NCT06574347 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
  NCT06343064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study PLB1004 for Lung cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.